证券代码：688617 证券简称：惠泰医疗 深圳惠泰医疗器械股份有限公司 2025年第三次临时股东会 会议资料 2025 年 11 月 | 2025 | 年第三次临时股东会会议须知 | 2 | | --- | --- | --- | | 2025 | 年第三次临时股东会会议议程 | 4 | | 2025 | 年第三次临时股东会议案 | 6 | | 议案一 | 6 | | | | 《关于公司董事会换届选举第三届董事会非独立董事的议案》 | 6 | | 议案二 | 11 | | 深圳惠泰医疗器械股份有限公司 2025 年第三次临时股东会会议资料 2025 年第三次临时股东会会议须知 为了维护全体股东的合法权益，确保公司股东会的正常秩序和议事效率，根 据《中华人民共和国公司法》（以下简称《公司法》）、《中华人民共和国证券 法》（以下简称《证券法》）、《上市公司股东会规则》以及《深圳惠泰医疗器 械股份有限公司章程》（以下简称《公司章程》）等相关规定，深圳惠泰医疗器 械股份有限公司（以下简称"公司"或"惠泰医疗"）特制订以下会议须知，请 出席股东会的全体人员遵照执行。 一、会议期间，全体出席人员应以维护股东的合法权益、 ...

Investment Rating - The report maintains a "Strong Buy" rating for the company [4] Core Views - The company reported a revenue of 1.867 billion yuan for the first three quarters of 2025, representing a year-on-year growth of 22.47%, with a net profit attributable to shareholders of 623 million yuan, up 18.02% year-on-year [1] - The third quarter revenue reached 654 million yuan, showing a year-on-year increase of 24.77%, while the net profit attributable to shareholders was 198 million yuan, growing 6.77% year-on-year [1] - The company is increasing its investment in the electrophysiology business, with expectations for rapid growth in PFA procedures and improvements in product offerings [7] - The market share in vascular intervention is steadily increasing, driven by new product iterations and a focus on enhancing existing product lines [7] - The gross margin remains stable, although profit growth in Q3 has slowed due to increased investments [7] - Revenue forecasts for 2025-2027 are adjusted to 2.561 billion, 3.339 billion, and 4.350 billion yuan, with corresponding net profits of 836 million, 1.057 billion, and 1.380 billion yuan, reflecting growth rates of 24%, 26%, and 31% respectively [7] Financial Data and Valuation - Total revenue for 2023 is projected at 1.650 billion yuan, with a year-on-year growth of 36% [3] - The company’s PE ratio is expected to decrease from 75.3 in 2023 to 29.1 by 2027, indicating improving valuation metrics [10] - The company’s ROE is projected to remain strong at around 29% over the forecast period [10] - The gross margin is expected to improve slightly from 71.3% in 2023 to 73.7% by 2027 [10] Stock Performance - The stock has shown a relative performance of -10% over the past month and a 24% increase over the past year [6]

Macroeconomic Insights - Global asset performance shows mixed results, with the Hang Seng Index up 1.29% and the Shanghai Composite Index up 1.08%, while developed markets like the S&P 500 fell by 1.63%[6] - In October, the U.S. ISM Manufacturing PMI declined, indicating economic slowdown, while consumer confidence continued to drop according to the University of Michigan index[7] Inflation and Prices - October CPI in China rose by 0.2% year-on-year, while PPI decreased by 2.1%, indicating a stable inflation environment with core service prices reaching their highest level since March 2024[11] - The rise in core CPI is attributed to reduced food drag and increased service contributions, with gold prices significantly impacting jewelry costs[13] Trade and Exports - In October, China's exports fell by 1.1% year-on-year, while imports grew by 1.0%, leading to a slight decrease in trade surplus[16] - The export structure shows weakness in non-U.S. markets, particularly the EU, while exports to the U.S. and ASEAN remained strong[18] Investment Strategies - The asset allocation report suggests an overweight position in Chinese A-shares and industrial commodities, with equity allocation set at 45% and bonds at 45%[22] - The report emphasizes the importance of AI industry trends and the potential for volatility in global equity markets, recommending a focus on quality assets[23] Market Dynamics - The trading activity has decreased, with turnover rates and transaction volumes declining across indices, indicating a cautious market sentiment[28] - The report highlights a decrease in northbound capital flow, with a net outflow of 2.6 billion CNY in the recent week, reflecting investor sentiment shifts[34]

Investment Rating - The report maintains an "Outperform" rating for the company [4][11]. Core Insights - The company continues to experience robust revenue growth, with a projected revenue of RMB 2.698 billion for 2025, reflecting a year-on-year increase of 30.6% [3][4]. - Net profit attributable to shareholders is expected to reach RMB 870 million in 2025, representing a growth of 29.2% compared to the previous year [3][4]. - The target price for the stock is set at RMB 333.05, with a target PE of 54X for 2025 [4][11]. Financial Summary - Total revenue for the first three quarters of 2025 was RMB 1.867 billion, with a net profit of RMB 623 million [4][11]. - Q3 2025 revenue was RMB 654 million, with a net profit of RMB 198 million [4][11]. - Forecasted EPS for 2025-2027 is RMB 6.17, RMB 8.09, and RMB 10.50 respectively [4][11]. Business Development - The volume of PFA surgeries is rapidly increasing, with expectations to exceed 5,000 procedures in 2025 [12][4]. - The company has expanded its promotion team to over 200 sales and on-site engineers, aiming for a 10%-20% annual increase in on-site volume per engineer [12][4]. - Increased investment in PFA promotion and R&D is evident, with Q3 2025 sales expenses at RMB 125 million and R&D expenses at RMB 98 million [13][4]. Market Position - The company holds approximately 20% market share in coronary business and over 30% in tumor intervention access products [14][4]. - Growth in the coronary and peripheral business is driven by existing product lines and the introduction of iterative products post volume-based procurement [14][4].

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical sector, specifically recommending the innovative drug and medical device industry chain [5][10]. Core Insights - The pharmaceutical sector shows a positive recovery trend in Q3 2025, with overall revenue growth of 0.6% year-on-year and a net profit increase of 0.3% year-on-year. This indicates a return to growth after previous declines [6][13]. - Specific segments such as medical devices and medical research outsourcing are experiencing significant growth, with revenue and net profit growth rates of 10.6% and 0.6% for medical devices, and 10.9% and 47.9% for medical research outsourcing, respectively [13][14]. - The report highlights a continued recommendation for specific A-share and H-share stocks, including 恒瑞医药 (Hengrui Medicine), 科伦药业 (Kelun Pharmaceutical), and others, indicating strong potential for investment [7][10]. Summary by Sections 1. Continued Recommendation for Innovative Drug and Medical Device Industry Chain - The report continues to recommend the innovative drug and medical device industry chain, maintaining "Overweight" ratings for several A-share stocks including 恒瑞医药, 科伦药业, and others, and H-share stocks like 翰森制药 and 三生制药 [7][10]. 2. Recovery Trend in Pharmaceutical Sector Q3 2025 - The pharmaceutical sector's overall revenue increased by 0.6% year-on-year in Q3 2025, with net profit rising by 0.3%. Medical devices and medical research outsourcing are leading this recovery with notable growth rates [13][14]. 3. Performance of Pharmaceutical Sector in October 2025 - In October 2025, the pharmaceutical sector underperformed compared to the broader market, with the SW pharmaceutical index declining by 1.8% while the Shanghai Composite Index rose by 1.9% [15][26]. 4. Performance of Hong Kong and US Pharmaceutical Sectors - The Hong Kong pharmaceutical sector also underperformed, with the Hang Seng Healthcare index down by 11.1%, while the US pharmaceutical sector showed strength with a 3.5% increase in the S&P healthcare index [26][27]. 5. Valuation and Premium Levels - As of October 31, 2025, the pharmaceutical sector's premium level relative to all A-shares is at a normal level, with a current relative premium rate of 76.7% [25][28].

Investment Rating - The report maintains a focus on innovative pharmaceuticals and medical devices, highlighting key A-share and H-share targets for investment [6][32]. Core Insights - The pharmaceutical sector showed a good recovery in Q3 2025, with overall revenue increasing by 0.6% year-on-year and net profit attributable to shareholders rising by 0.3% year-on-year [11][32]. - Medical equipment benefited from procurement recovery, with Q3 revenue and net profit growth of 10.6% and 0.6% year-on-year, respectively [11][32]. - Medical R&D outsourcing continued to achieve high growth, with Q3 revenue and net profit growth of 10.9% and 47.9% year-on-year [11][32]. - The offline pharmacy sector improved, with Q3 revenue and net profit growth of 2.1% and 37.8% year-on-year [11][32]. Summary by Sections 1. Focus on Innovative Pharmaceuticals and Medical Devices - Key A-share targets include Jiangsu Heng Rui Medicine, Sichuan Kelun Pharmaceutical, Huadong Medicine, Changchun High-tech Industry, Jiangsu Nhwa Pharmaceutical, WuXi AppTec, Hangzhou Tigermed Consulting, Lepu Medical, APT Medical, and related target Guangdong Zhongsheng Pharmaceutical [6][32]. - Key H-share targets include Hansoh Pharmaceutical Group, 3SBio, Akeso, and related target Innovent Biologics, WuXi AppTec [6][32]. 2. Q3 2025 Pharmaceutical Sector Recovery - The pharmaceutical sector's overall revenue increased by 0.6% year-on-year, with net profit attributable to shareholders up by 0.3% year-on-year [11][32]. - Specific segments such as medical devices and medical R&D outsourcing showed significant growth [11][32]. 3. October 2025 Market Performance - In October 2025, the pharmaceutical sector underperformed the market, with the SW Pharmaceutical and Biological index falling by 1.8% while the SHCOMP rose by 1.9% [14][32]. - The relative premium of the pharmaceutical sector compared to all A-shares was at a normal level, with a current relative premium rate of 76.7% [23][32]. 4. Hong Kong and U.S. Market Performance - The Hong Kong pharmaceutical sector underperformed, with the Hang Seng Healthcare index falling by 11.1% [24][32]. - In contrast, the U.S. S&P 500 healthcare sector rose by 3.5% [24][32].

Core Viewpoint - The biopharmaceutical sector on the STAR Market has shown mixed performance, with the STAR Biopharmaceutical Index declining by 0.60% as of November 6, 2025, while individual stocks exhibited varied movements, indicating a potential for structural recovery in the sector [1][4]. Group 1: Market Performance - The STAR Biopharmaceutical Index decreased by 0.60% as of November 6, 2025, with stocks like Huaheng Biological leading gains at 2.86%, while Yifang Biological experienced the largest decline [1]. - The Jiashi STAR Biopharmaceutical ETF recorded a turnover of 6.67% and a transaction volume of 21.39 million yuan, reaching a new high of 322 million yuan in scale, ranking first among comparable funds [3]. - The Jiashi STAR Biopharmaceutical ETF has seen a net inflow of 56.85 million yuan over the past four days, with a peak single-day net inflow of 16.85 million yuan [3]. Group 2: Fund Performance - As of November 5, 2025, the Jiashi STAR Biopharmaceutical ETF has achieved a one-year net value increase of 26.53%, with the highest monthly return since inception being 23.29% and the longest consecutive monthly gain lasting seven months [3]. - The average monthly return during the rising months of the Jiashi STAR Biopharmaceutical ETF is 7.85% [3]. Group 3: Industry Outlook - Recent adjustments in the pharmaceutical sector are attributed to a recovery in capital market financing and an increase in the scale of innovative drug exports, leading to a rebound in domestic innovative drug research and development [3]. - The outlook for the innovative drug sector remains focused on business development (BD) expectations, with BD activities typically accounting for about 40% of annual transactions in the fourth quarter [3]. - According to data, the top ten weighted stocks in the STAR Biopharmaceutical Index account for 49.74% of the index, indicating a concentration of investment in key players [4][6].

Group 1 - The A-share market opened lower on November 5, with the three major indices declining collectively. The Kexin 50 ETF (588000) experienced a maximum drop of over 1.65% after an initial rise [1] - The Kexin 50 ETF (588000) has attracted significant capital recently, with inflows of 1.629 billion yuan over the last 5 trading days, 1.408 billion yuan over the last 10 days, and 2.721 billion yuan over the last 20 days. Its trading volume exceeded 1.5 billion yuan, ranking first among similar products [1] - Amazon Web Services (AWS) signed a $38 billion computing power cooperation agreement with OpenAI, which will utilize AWS's latest GPU resources for various AI tasks. This collaboration is expected to enhance the global AI computing infrastructure and drive continuous demand in the cloud computing and AI industry [1] Group 2 - Changjiang Securities noted that the artificial intelligence industry has entered a "virtuous cycle" development phase, marking the beginning of a new computing era. The global computing infrastructure is still in its early stages, with a complete development cycle expected to last at least 10 years [2] - The AI wave is driving rapid growth for domestic and international cloud service providers, with capital expenditure expectations continuously being revised upward, leading to increased investment in computing power [2] - The Kexin 50 ETF (588000) tracks the Kexin 50 Index, with 69.3% of its holdings in the electronics sector and 5.17% in the computer sector, totaling 74.47%. This aligns well with the development direction of cutting-edge industries such as AI and robotics, while also covering various high-tech fields like medical devices and software development [2]

Group 1 - The company Huatai Medical announced the nomination of candidates for its third board of directors, including both non-independent and independent directors [2] - The nominated non-independent directors are Ge Hao, Li Xinsong, Zhao Yun, Zhao Yuxiang, and Cheng Zhenghui [2] - The nominated independent directors include Sun Lefe, Li Guangxian, and Bai Yunxia, with Bai Yunxia being a professional accountant [2]

证券代码：688617 证券简称：惠泰医疗 公告编号：2025-048 深圳惠泰医疗器械股份有限公司（以下简称"公司"）第二届董事会任期即 将届满。根据《中华人民共和国公司法》（以下简称《公司法》）、《上海证券 交易所科创板股票上市规则》《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》等法律、法规以及《深圳惠泰医疗器械股份有限公司章程》 （以下简称《公司章程》）等相关规定，公司开展董事会换届选举工作，现将具 一、董事会换届选举情况 根据《公司章程》的规定，公司董事会由 9 名董事组成，其中独立董事 3 名，职工代表董事 1 名。 公司于 2025 年 10 月 27 日召开第二届董事会提名委员会第五次会议，审议 通过《关于提名公司第三届董事会非独立董事候选人的议案》《关于提名公司第 三届董事会独立董事候选人的议案》及《关于提名公司第三届董事会职工代表董 事候选人的议案》；于 2025 年 11 月 5 日召开第二届董事会第二十六次会议，审 议通过《关于公司董事会换届选举暨提名第三届董事会非独立董事候选人的议案》 及《关于公司董事会换届选举暨提名第三届董事会独立董事候选人的议案》。 深圳惠泰医 ...